2019 CYIR Finalized

28 OCS sparing strategies are sorely needed and recommend- ed below are two manuscripts that address OCS avoid- ance using high dose inhaled steroids. In addition, OCS exposure should be taken into serious consideration as an indication for initiating biologic therapy in patients with type II high asthma. Strategies for OCS sparing in T helper type II low asthma are still lacking at this time and represent an area of significant need. Comments 1. Adverse effects of OCS are noted at cumulative doses of 1.0 to <2.5grams which is equivalent to four lifetime courses of OCS. 2. OCS toxicity began to occur within a few years of initial expo- sure. 3. Clinicians should take OCS exposure into consideration when managing asthma and consider OCS sparing strategies early in the course of disease to avoid long term co-morbidities. BIOLOGICS FOR TYPE II ASTHMA EXPAND TO COVER NEW MECHANISMS Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475-85. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486-96. Summary Targeted therapies for T helper type II asthma have been focused on IL-5 mediated eosinophilic inflammation and allergic asthma with elevated IgE and sensitization to aller- gens. Type II asthma also encompasses IL4/IL13-driven disease with increased fraction of exhaled nitric oxide (FeNO) and evidence of airways hyper responsiveness and mucous hypersecretion. IL13-mediated inflammation is critical in promoting globlet cell hyperplasia, mucous hypersecretion that results in airway remodeling as well as upregulation of inducible nitric oxide synthase (iNOS). Prior attempts to modulate IL-13-mediated inflammation with anti-IL13 antibiodies failed to demonstrate improve- ments in asthma exacerbations and lung function. IL13 binds both the IL13 receptor and IL4-R alpha and thus can be modulated via antibiodies that target this receptor. These phase 3 studies assessed the effect of dupilumab on asthma demonstrated clinical efficacy and dupilumab was approved for an asthma indication by the FDA in November 2018. It remains unclear why singularly blocking IL13 medi- ated effects was not adequate in ameliorating asthma. Dupilumab is beneficial for type II asthma and works best in patients with elevated FeNO and eosinophils. The impact on eosinophils is not fully understood but is postulated to be the result of alterations in eotaxin-3 levels resulting in an inability of eosinophils to hone into tissues. The mechanis- tic bronchoscopy study with dupilumab will likely answer further questions about the impact of this therapy on eosin- ophilic infiltration into the airways of patients with asthma. Comments 1. Dupilumab demonstrates efficacy in patients with moderate to severe persistent asthma with T helper type II features (elevated eosinophils and FeNO) with a significant reduction in exacerba- tions and improvements in FEV1. 2. Dupilumab significantly decreased oral corticosteroid (OCS) dose in patients with OCS dependent asthma. It is approved in this population regardless of underlying eosinophil count. 3. There are transient elevations in eosinophils for approximately four months following initiation of dupixent and caution must be exercised in prescribing dupixent to patients with blood eosino- phils >1500. 4. A marked and immediate reduction in FeNO occurs within two weeks of initiating dupixent therapy. 5. Serum IgE level decreased over the one year period of the study in patients treated with dupixent. This effect is likely related to modulation of B-cell switching that is mediated by IL4. OTHER ARTICLES OF INTEREST Prevention of Asthma Exacerbations Using High Dose Inhaled Steroids During Initial Loss of Asthma Control Jackson DJ, Bacharier LB, Mauger DT, Boehmer S, Beigelman A, Chmiel JF, Fitzpatrick AM, Gaffin JM, Morgan WJ, Peters SP, Phipatanakul W, Sheehan WJ, Cabana MD, Holguin F, Martinez FD, Pongracic JA, Baxi SN, Benson M, Blake K, Covar R, Gentile DA, Israel E, Krishnan JA, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Long D, Ly N, Marbin J, Moy JN, Myers RE, Olin JT, Raissy HH, Robison RG, Ross K, Sorkness CA, Lemanske RF, Jr., National Heart L, Blood Institute A. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. N Engl J Med. 2018;378(10):891-901. McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, Pavord I, Price D, Duley L, Thomas M, Bradshaw L, Higgins B, Haydock R, Mitchell E, Devereux G, Harrison T. Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. N Engl J Med. 2018;378(10):902- 10. Impact of Clinical Characteristics and Asthma Phenotypes on ASTHMA

RkJQdWJsaXNoZXIy MTM1ODMw